表紙
市場調査レポート

Bayer AG : パイプライン製品分析

Bayer AG - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 224545
出版日 ページ情報 英文 250 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
Bayer AG : パイプライン製品分析 Bayer AG - Product Pipeline Review - 2016
出版日: 2016年04月30日 ページ情報: 英文 250 Pages
概要

Bayer AGは、世界有数のヘルスケア企業です。投資持ち株会社には、系列会社(Bayer HealthCare、Bayer CropScience、Bayer MaterialScience、Bayer Business Services、Bayer Technology Services and Currenta)も含まれます。

当レポートでは、Bayer AGによる治療用パイプライン製品の開発状況について調査分析し、研究・開発の概要、パイプライン製品の概要、治験の段階別の製品の概要、薬剤プロファイル、パイプライン分析、企業情報などについて、体系的な情報を提供しています。

目次

Bayer AGの概要

Bayer AG - 研究・開発の概要

  • 主要治療分野

Bayer AG - パイプライン検証

  • パイプライン製品:開発段階別
  • パイプライン製品 - 単独療法
  • パイプライン製品 - 併用療法
  • パイプライン製品 - 提携製品
  • パイプライン製品 - アウトライセンス製品

Bayer AG - パイプライン製品の概要

  • パイプライン製品 - 後期段階のパイプライン製品
  • パイプライン製品 - 治験段階のパイプライン製品
  • パイプライン製品 - 初期段階のパイプライン製品
  • パイプライン製品 - 未確認段階のパイプライン製品

Bayer AG - 薬剤プロファイル

  • aflibercept
  • BAY-818973
  • radium Ra 223 dichloride
  • rivaroxaban
  • (nifedipine + candesartan cilexetil)
  • amikacin sulfate
  • ciprofloxacin
  • copanlisib hydrochloride
  • damoctocog alfa pegol
  • dienogest
  • mapracorat
  • regorafenib
  • sorafenib tosylate
  • tedizolid phosphate
  • (anastrozole + levonorgestrel)
  • anetumab ravtansine
  • BAY-1067197
  • BAY-1142524
  • BAY-858501
  • finerenone
  • molidustat
  • refametinib
  • riociguat
  • roniciclib
  • vericiguat
  • vilaprisan
  • BAY sGCstim
  • BAY-1082439
  • BAY-1093884
  • BAY-1097761
  • BAY-1112054
  • BAY-1125976
  • BAY-1128688
  • BAY-1129980
  • BAY-1143269
  • BAY-1143572
  • BAY-1161909
  • BAY-1163877
  • BAY-1179470
  • BAY-1187982
  • BAY-1213790
  • BAY-1214784
  • BAY-1217389
  • BAY-1238097
  • Drug for Diabetic Foot Ulcer
  • Drug to Antagonize GnRH Receptor for Endometriosis and Uterine Leiomyoma
  • Monoclonal Antibodies for Cancer
  • Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis
  • Small Molecule to Inhibit Kinase for Inflammation and Cancer
  • Vaccine for Follicular Lymphoma
  • BAY sGCact
  • BAY-1001931
  • BAY-1024767
  • BAY-606583
  • Bay-846
  • BR-5489
  • Monoclonal Antibodies for Undisclosed Indication
  • Protein To Inhibit HER-2 Receptor for Breast Cancer
  • Protein to Inhibit PDGFR-Beta Receptor for Solid Tumors
  • Small Molecule to Inhibit Plasminogen for Rare Bleeding Disorder
  • Small Molecules to Inhibit Wnt Pathway for Cancer
  • ZK-191784
  • ZK-216348
  • Drugs for Endometriosis and Uterine Fibroids
  • Monoclonal Antibody Conjugated to Target CD22 for Hematological Cancers
  • Recombinant Protein for Solid Tumors
  • Small Molecule to Inhibit Epigenetic Target for Cancer
  • Small Molecules for Cancer
  • Immunotherapy for Cancer

Bayer AG - パイプライン分析

  • パイプライン製品:標的別
  • パイプライン製品:投与経路別
  • パイプライン製品:分子タイプ別
  • パイプライン製品:作用機序別

Bayer AG - パイプライン製品の最新動向

Bayer AG - 休止状態のプロジェクト

Bayer AG - 中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル

Bayer AG - 企業発表

Bayer AG - 本社所在地と子会社

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08042CDB

Summary

Global Markets Direct's, 'Bayer AG - Product Pipeline Review - 2016', provides an overview of the Bayer AG's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Bayer AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Bayer AG
  • The report provides overview of Bayer AG including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Bayer AG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Bayer AG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Bayer AG's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Bayer AG
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bayer AG's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bayer AG Snapshot
    • Bayer AG Overview
    • Key Information
    • Key Facts
  • Bayer AG - Research and Development Overview
    • Key Therapeutic Areas
  • Bayer AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Bayer AG - Pipeline Products Glance
  • Bayer AG - Late Stage Pipeline Products
  • Bayer AG - Clinical Stage Pipeline Products
  • Bayer AG - Early Stage Pipeline Products
  • Bayer AG - Unknown Stage Pipeline Products
  • Bayer AG - Drug Profiles
    • aflibercept
    • dienogest
    • Kovaltry
    • (candesartan cilexetil + nifedipine)
    • amikacin sulfate
    • ciprofloxacin hydrochloride
    • copanlisib hydrochloride
    • damoctocog alfa pegol
    • finerenone
    • nifurtimox
    • radium Ra 223 dichloride
    • regorafenib
    • rivaroxaban
    • tedizolid phosphate
    • (anastrozole + levonorgestrel)
    • anetumab ravtansine
    • BAY-1067197
    • BAY-1142524
    • molidustat
    • refametinib
    • riociguat
    • roniciclib
    • vericiguat
    • vilaprisan
    • sorafenib tosylate
    • BAY sGCstim
    • BAY-1082439
    • BAY-1093884
    • BAY-1112054
    • BAY-1125976
    • BAY-1128688
    • BAY-1129980
    • BAY-1143269
    • BAY-1143572
    • BAY-1161909
    • BAY-1163877
    • BAY-1179470
    • BAY-1187982
    • BAY-1213790
    • BAY-1214784
    • BAY-1217389
    • BAY-1251152
    • BAY-1862864
    • Drug for Diabetic Foot Ulcer
    • Monoclonal Antibodies for Oncology
    • Monoclonal Antibody Conjugate to Target CD22 for Hematological Cancers
    • Monoclonal Antibody for Undisclosed Indication
    • Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis
    • Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders
    • Small Molecule to Inhibit Kinase for Inflammation and Oncology
    • BAY sGCact
    • BAY-1001931
    • BAY-1024767
    • BAY-1436032
    • BAY-606583
    • Bay-846
    • Immunotherapy for Oncology
    • Monoclonal Antibodies for Undisclosed Indication
    • Monoclonal Antibody to Inhibit CGEN-15001T for Oncology
    • Monoclonal Antibody to Inhibit CGEN-15022 for Oncology
    • Monocloncal Antibody Conjugate to Inhibit PDGFR-Beta Receptor for Solid Tumors
    • Recombinant Protein To Inhibit HER-2 Receptor for Breast Cancer
    • Small Molecule to Inhibit Plasminogen for Rare Bleeding Disorder
    • Small Molecules to Inhibit Mitogen Activated Protein Kinase Kinase for Oncology
    • Small Molecules to Inhibit MTH1 for Oncology
    • Small Molecules to Inhibit Wnt Pathway for Oncology
    • SMYD-2BAY02
    • ZK-191784
    • ZK-216348
    • Drugs for Endometriosis and Uterine Fibroids
    • Recombinant Protein for Solid Tumors
    • Small Molecule to Inhibit Epigenetic Target for Oncology
    • Small Molecules for Cardiovascular Disease
    • Small Molecules for Oncology
    • Small Molecules to Inhibit GLUT1 and GLUT2
    • Small Molecule for Undisclosed Indication
  • Bayer AG - Pipeline Analysis
    • Bayer AG - Pipeline Products by Target
    • Bayer AG - Pipeline Products by Route of Administration
    • Bayer AG - Pipeline Products by Molecule Type
    • Bayer AG - Pipeline Products by Mechanism of Action
  • Bayer AG - Recent Pipeline Updates
  • Bayer AG - Dormant Projects
  • Bayer AG - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Bayer AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Bayer AG, Key Information
  • Bayer AG, Key Facts
  • Bayer AG - Pipeline by Indication, 2016
  • Bayer AG - Pipeline by Stage of Development, 2016
  • Bayer AG - Monotherapy Products in Pipeline, 2016
  • Bayer AG - Combination Treatment Modalities in Pipeline, 2016
  • Bayer AG - Partnered Products in Pipeline, 2016
  • Bayer AG - Partnered Products/ Combination Treatment Modalities, 2016
  • Bayer AG - Out-Licensed Products in Pipeline, 2016
  • Bayer AG - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Bayer AG - Pre-Registration, 2016
  • Bayer AG - Phase III, 2016
  • Bayer AG - Phase II, 2016
  • Bayer AG - Phase I, 2016
  • Bayer AG - Preclinical, 2016
  • Bayer AG - Discovery, 2016
  • Bayer AG - Unknown, 2016
  • Bayer AG - Pipeline by Target, 2016
  • Bayer AG - Pipeline by Route of Administration, 2016
  • Bayer AG - Pipeline by Molecule Type, 2016
  • Bayer AG - Pipeline Products by Mechanism of Action, 2016
  • Bayer AG - Recent Pipeline Updates, 2016
  • Bayer AG - Dormant Developmental Projects,2016
  • Bayer AG - Discontinued Pipeline Products, 2016
  • Bayer AG, Subsidiaries

List of Figures

  • Bayer AG - Pipeline by Top 10 Indication, 2016
  • Bayer AG - Pipeline by Stage of Development, 2016
  • Bayer AG - Monotherapy Products in Pipeline, 2016
  • Bayer AG - Combination Treatment Modalities in Pipeline, 2016
  • Bayer AG - Partnered Products in Pipeline, 2016
  • Bayer AG - Out-Licensed Products in Pipeline, 2016
  • Bayer AG - Pipeline by Top 10 Target, 2016
  • Bayer AG - Pipeline by Top 10 Route of Administration, 2016
  • Bayer AG - Pipeline by Top 10 Molecule Type, 2016
  • Bayer AG - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top